184 related articles for article (PubMed ID: 30782595)
1. A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to Alkaptonuria.
Norman BP; Davison AS; Ross GA; Milan AM; Hughes AT; Sutherland H; Jarvis JC; Roberts NB; Gallagher JA; Ranganath LR
Clin Chem; 2019 Apr; 65(4):530-539. PubMed ID: 30782595
[TBL] [Abstract][Full Text] [Related]
2. Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism.
Norman BP; Davison AS; Hughes JH; Sutherland H; Wilson PJ; Berry NG; Hughes AT; Milan AM; Jarvis JC; Roberts NB; Ranganath LR; Bou-Gharios G; Gallagher JA
Genes Dis; 2022 Jul; 9(4):1129-1142. PubMed ID: 35685462
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC-QTOF-MS.
Davison AS; Norman BP; Ross GA; Hughes AT; Khedr M; Milan AM; Gallagher JA; Ranganath LR
JIMD Rep; 2019 Jul; 48(1):67-74. PubMed ID: 31392115
[TBL] [Abstract][Full Text] [Related]
4. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
Hughes JH; Wilson PJM; Sutherland H; Judd S; Hughes AT; Milan AM; Jarvis JC; Bou-Gharios G; Ranganath LR; Gallagher JA
J Inherit Metab Dis; 2020 Mar; 43(2):259-268. PubMed ID: 31503358
[TBL] [Abstract][Full Text] [Related]
5. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
Preston AJ; Keenan CM; Sutherland H; Wilson PJ; Wlodarski B; Taylor AM; Williams DP; Ranganath LR; Gallagher JA; Jarvis JC
Ann Rheum Dis; 2014 Jan; 73(1):284-9. PubMed ID: 23511227
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of para-Hydroxyphenylpyruvate Dioxygenase by Analogues of the Herbicide Nitisinone As a Strategy to Decrease Homogentisic Acid Levels, the Causative Agent of Alkaptonuria.
Laschi M; Bernardini G; Dreassi E; Millucci L; Geminiani M; Braconi D; Marzocchi B; Botta M; Manetti F; Santucci A
ChemMedChem; 2016 Apr; 11(7):674-8. PubMed ID: 26947423
[TBL] [Abstract][Full Text] [Related]
7. Assessing the effect of nitisinone induced hypertyrosinaemia on monoamine neurotransmitters in brain tissue from a murine model of alkaptonuria using mass spectrometry imaging.
Davison AS; Strittmatter N; Sutherland H; Hughes AT; Hughes J; Bou-Gharios G; Milan AM; Goodwin RJA; Ranganath LR; Gallagher JA
Metabolomics; 2019 Apr; 15(5):68. PubMed ID: 31037385
[TBL] [Abstract][Full Text] [Related]
8. Nitisinone causes acquired tyrosinosis in alkaptonuria.
Khedr M; Cooper MS; Hughes AT; Milan AM; Davison AS; Norman BP; Sutherland H; Jarvis JC; Fitzgerald R; Markinson L; Psarelli EE; Ghane P; Deutz NEP; Gallagher JA; Ranganath LR
J Inherit Metab Dis; 2020 Sep; 43(5):1014-1023. PubMed ID: 32083330
[TBL] [Abstract][Full Text] [Related]
9. Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone.
Curtis SL; Norman BP; Milan AM; Gallagher JA; Olsson B; Ranganath LR; Roberts NB
Clin Biochem; 2019 Sep; 71():24-30. PubMed ID: 31228435
[TBL] [Abstract][Full Text] [Related]
10. The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool.
Milan AM; Hughes AT; Davison AS; Devine J; Usher J; Curtis S; Khedr M; Gallagher JA; Ranganath LR
Ann Clin Biochem; 2017 May; 54(3):323-330. PubMed ID: 28081634
[TBL] [Abstract][Full Text] [Related]
11. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.
Ranganath LR; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Griffin R; Psarelli EE; Cox TF; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA
Mol Genet Metab; 2018 Sep; 125(1-2):127-134. PubMed ID: 30055994
[TBL] [Abstract][Full Text] [Related]
12. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.
Ranganath LR; Milan AM; Hughes AT; Dutton JJ; Fitzgerald R; Briggs MC; Bygott H; Psarelli EE; Cox TF; Gallagher JA; Jarvis JC; van Kan C; Hall AK; Laan D; Olsson B; Szamosi J; Rudebeck M; Kullenberg T; Cronlund A; Svensson L; Junestrand C; Ayoob H; Timmis OG; Sireau N; Le Quan Sang KH; Genovese F; Braconi D; Santucci A; Nemethova M; Zatkova A; McCaffrey J; Christensen P; Ross G; Imrich R; Rovensky J
Ann Rheum Dis; 2016 Feb; 75(2):362-7. PubMed ID: 25475116
[TBL] [Abstract][Full Text] [Related]
13. Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of Alkaptonuria.
Davison AS; Norman BP; Sutherland H; Milan AM; Gallagher JA; Jarvis JC; Ranganath LR
Metabolites; 2022 May; 12(6):. PubMed ID: 35736410
[TBL] [Abstract][Full Text] [Related]
14. Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry.
Hughes AT; Milan AM; Davison AS; Christensen P; Ross G; Gallagher JA; Dutton JJ; Ranganath LR
Ann Clin Biochem; 2015 Sep; 52(Pt 5):597-605. PubMed ID: 25628464
[TBL] [Abstract][Full Text] [Related]
15. Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria.
Milan AM; Hughes AT; Davison AS; Khedr M; Rovensky J; Psarelli EE; Cox TF; Rhodes NP; Gallagher JA; Ranganath LR
Sci Rep; 2019 Jul; 9(1):10024. PubMed ID: 31296884
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of low dose nitisinone in the management of alkaptonuria.
Sloboda N; Wiedemann A; Merten M; Alqahtani A; Jeannesson E; Blum A; Henn-Ménétré S; Guéant JL; Renard E; Feillet F
Mol Genet Metab; 2019 Jul; 127(3):184-190. PubMed ID: 31235217
[TBL] [Abstract][Full Text] [Related]
17. Use of nitisinone in patients with alkaptonuria.
Suwannarat P; O'Brien K; Perry MB; Sebring N; Bernardini I; Kaiser-Kupfer MI; Rubin BI; Tsilou E; Gerber LH; Gahl WA
Metabolism; 2005 Jun; 54(6):719-28. PubMed ID: 15931605
[TBL] [Abstract][Full Text] [Related]
18. Preventive use of nitisinone in alkaptonuria.
Wolffenbuttel BHR; Heiner-Fokkema MR; van Spronsen FJ
Orphanet J Rare Dis; 2021 Aug; 16(1):343. PubMed ID: 34344451
[TBL] [Abstract][Full Text] [Related]
19. Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria.
Mistry JB; Jackson DJ; Bukhari M; Taylor AM
Clin Rheumatol; 2016 Feb; 35(2):513-6. PubMed ID: 26024586
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biochemical assessment of depressive symptoms in patients with Alkaptonuria before and after two years of treatment with nitisinone.
Davison AS; Harrold JA; Hughes G; Norman BP; Devine J; Usher J; Hughes AT; Khedr M; Gallagher JA; Milan AM; J C G H; Ranganath LR
Mol Genet Metab; 2018 Sep; 125(1-2):135-143. PubMed ID: 30049652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]